Hongxiu Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hongxiu Han has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Guohua Zhang
Department of Physiology, Shanghai Jiaotong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China
4 shared publications Weifang Rong
Songjiang Institute and Department of Anatomy and Physiology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China
2 shared publications- Yan Yang
Department of Pathology, Shanghai First Maternity and Infant Healthy Hospital, Tongji University, 536 Changle Road, Shanghai 200040, China
2 shared publications Yueting Kou
Songjiang Institute and Department of Anatomy and Physiology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China
2 shared publicationsChanghao Han
Department of Clinical Medicine, Second Clinical Medical College, Chongqing Medical University, Chongqing, China
1 shared publication- Chunxue Yang
Department of Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 2 February 2024
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (5) , 785-795
5-Hydroxytryptamine 4 Receptor Agonist Attenuates Diabetic Enteric Neuropathy through Inhibition of the Receptor-Interacting Protein Kinase 3 Pathway
- 2 February 2024
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (5) , 785-795
Open Access5-Hydroxytryptamine 4 Receptor Agonist Attenuates Diabetic Enteric Neuropathy through Inhibition of the Receptor-Interacting Protein Kinase 3 Pathway
- 28 September 2023
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 55 (12) , 1874-1883
Activation of the 5-hydroxytryptamine 4 receptor ameliorates tight junction barrier dysfunction in the colon of type 1 diabetic mice
Hyperglycemia drives dysfunction of the intestinal barrier. 5-Hydroxytryptaine 4 receptor (5-HT4R) agonists have been considered therapeutics for constipation in the clinic. However, the roles of 5-HT4R activation in mucosa should be fully realized. Here, we investigate the effects of 5-HT4R activation on diabetes-induced disruption of the tight junction (TJ) barrier in the colon. Not surprisingly, the TJ barrier in diabetic mice with or without 5-HT4R is tremendously destroyed, as indicated by increased serum fluorescein isothiocyanate (FITC)-dextran and decreased transepithelial electrical resistance (TER). Simultaneously, decreased expressions of TJ proteins are shown in both wild type (WT) and 5-HT4R KO mice with diabetes. Notably, chronic treatment with intraperitoneal injection of a 5-HT4R agonist in WT mice with diabetes repairs the TJ barrier and promoted TJ protein expressions, including occludin, claudin-1 and ZO-1, in the colon, whereas a 5-HT4R agonist does not improve TJ barrier function or TJ protein expressions in 5-HT4R KO mice with diabetes. Furthermore, stimulation of 5-HT4R inhibits diabetes-induced upregulation of myosin light chain kinase (MLCK), Rho-associated coiled coil protein kinase 1 (ROCK1), and phosphorylated myosin light chain (p-MLC), which are key molecules that regulate TJ integrity, in the colonic mucosa of WT mice. However, such action induced by a 5-HT4R agonist is not observed in 5-HT4R KO mice with diabetes. These findings indicate that 5-HT4R activation may restore TJ integrity by inhibiting the expressions of MLCK, ROCK1, and p-MLC, improving epithelial barrier function in diabetes.
- 28 September 2023
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 55 (12) , 1874-1883
Activation of the 5-hydroxytryptamine 4 receptor ameliorates tight junction barrier dysfunction in the colon of type 1 diabetic mice
Hyperglycemia drives dysfunction of the intestinal barrier. 5-Hydroxytryptaine 4 receptor (5-HT4R) agonists have been considered therapeutics for constipation in the clinic. However, the roles of 5-HT4R activation in mucosa should be fully realized. Here, we investigate the effects of 5-HT4R activation on diabetes-induced disruption of the tight junction (TJ) barrier in the colon. Not surprisingly, the TJ barrier in diabetic mice with or without 5-HT4R is tremendously destroyed, as indicated by increased serum fluorescein isothiocyanate (FITC)-dextran and decreased transepithelial electrical resistance (TER). Simultaneously, decreased expressions of TJ proteins are shown in both wild type (WT) and 5-HT4R KO mice with diabetes. Notably, chronic treatment with intraperitoneal injection of a 5-HT4R agonist in WT mice with diabetes repairs the TJ barrier and promoted TJ protein expressions, including occludin, claudin-1 and ZO-1, in the colon, whereas a 5-HT4R agonist does not improve TJ barrier function or TJ protein expressions in 5-HT4R KO mice with diabetes. Furthermore, stimulation of 5-HT4R inhibits diabetes-induced upregulation of myosin light chain kinase (MLCK), Rho-associated coiled coil protein kinase 1 (ROCK1), and phosphorylated myosin light chain (p-MLC), which are key molecules that regulate TJ integrity, in the colonic mucosa of WT mice. However, such action induced by a 5-HT4R agonist is not observed in 5-HT4R KO mice with diabetes. These findings indicate that 5-HT4R activation may restore TJ integrity by inhibiting the expressions of MLCK, ROCK1, and p-MLC, improving epithelial barrier function in diabetes.
- 1 March 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (3) , 515-526
Vascular Endothelial Growth Factor Mediates the Sprouted Axonogenesis of Breast Cancer in Rat
- 1 March 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (3) , 515-526
Vascular Endothelial Growth Factor Mediates the Sprouted Axonogenesis of Breast Cancer in Rat
- 1 November 2015
- Vol. 44 (11) , 825-7
[Research advance on biologic significance of neurogenesis in tumor and its underlying molecular mechanisms].
- 1 November 2015
- Vol. 44 (11) , 825-7
[Research advance on biologic significance of neurogenesis in tumor and its underlying molecular mechanisms].
- Open Access
- 4 July 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 484
The clinicopathological significance of neurogenesis in breast cancer
Background: Recent reports support a novel biological phenomenon about cancer related neurogenesis. However, little is known about the clinicopathological significance of neurogenesis in breast cancer. Methods: A total of 196 cases, including 20 of normal tissue, 14 of fibroadenoma, 18 of ductal carcinoma in situ (DCIS) and 144 of invasive ductal carcinoma (IDC) of the breast were used. The tissue slides were immunostained for protein gene product (PGP) 9.5 and S 100 to identify nerves. The correlation between the expression of PGP 9.5 and clinicopathological characteristics in IDC of the breast was assessed. Results: While the PGP 9.5 positive nerve fibers are identified in all cases of normal breast tissue controls and in the tumor stroma of 61% (89/144) cases of invasive ductal carcinomas, PGP 9.5 positive nerve fibers are not seen in the tumor stroma of cases of fibroadenoma and DCIS. The percentage of tumors that exhibited neurogenesis increased from tumor grade I to tumor grade II and III (29.4% vs 71.8%, p < 0.0001). In addition, patients with less than 3 years of disease-free survival tended to have a higher positive expression of PGP 9.5 compared to patients with an equal or more than 3 years of disease-free survival (64.8% vs 46.7%, p = 0.035). Furthermore, moderate/strong expression of PGP 9.5 was found to be significantly related to microvessel density (MVD, p = 0.014). Interestingly, PGP 9.5 expression was significantly associated with higher MVD in the ER-negative (p = 0.045) and node-negative (p = 0.039) subgroups of IDC of the breast. Conclusions: This data indicates that neurogenesis is associated with some aggressive features of IDC including tumor grade and patient survival as well as angiogenesis, especially in ER-negative and node-negative subtypes of IDC of the breast. Thus, neurogenesis appears to be associated with breast cancer progression and may play a role in therapeutic guidance for patients with ER-negative and node-negative invasive breast cancer.
- 4 July 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 484
Open AccessThe clinicopathological significance of neurogenesis in breast cancer
Background: Recent reports support a novel biological phenomenon about cancer related neurogenesis. However, little is known about the clinicopathological significance of neurogenesis in breast cancer. Methods: A total of 196 cases, including 20 of normal tissue, 14 of fibroadenoma, 18 of ductal carcinoma in situ (DCIS) and 144 of invasive ductal carcinoma (IDC) of the breast were used. The tissue slides were immunostained for protein gene product (PGP) 9.5 and S 100 to identify nerves. The correlation between the expression of PGP 9.5 and clinicopathological characteristics in IDC of the breast was assessed. Results: While the PGP 9.5 positive nerve fibers are identified in all cases of normal breast tissue controls and in the tumor stroma of 61% (89/144) cases of invasive ductal carcinomas, PGP 9.5 positive nerve fibers are not seen in the tumor stroma of cases of fibroadenoma and DCIS. The percentage of tumors that exhibited neurogenesis increased from tumor grade I to tumor grade II and III (29.4% vs 71.8%, p < 0.0001). In addition, patients with less than 3 years of disease-free survival tended to have a higher positive expression of PGP 9.5 compared to patients with an equal or more than 3 years of disease-free survival (64.8% vs 46.7%, p = 0.035). Furthermore, moderate/strong expression of PGP 9.5 was found to be significantly related to microvessel density (MVD, p = 0.014). Interestingly, PGP 9.5 expression was significantly associated with higher MVD in the ER-negative (p = 0.045) and node-negative (p = 0.039) subgroups of IDC of the breast. Conclusions: This data indicates that neurogenesis is associated with some aggressive features of IDC including tumor grade and patient survival as well as angiogenesis, especially in ER-negative and node-negative subtypes of IDC of the breast. Thus, neurogenesis appears to be associated with breast cancer progression and may play a role in therapeutic guidance for patients with ER-negative and node-negative invasive breast cancer.
- Open Access
- 5 July 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 59
Decreased D2-40 and increased p16INK4A immunoreactivities correlate with higher grade of cervical intraepithelial neoplasia
D2-40 has been shown a selective marker for lymphatic endothelium, but also shown in the benign cervical basal cells. However, the application of D2-40 immunoreactivity in the cervical basal cells for identifying the grade of cervical intraepithelial neoplasia (CIN) has not been evaluated.
- 5 July 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 59
Open AccessDecreased D2-40 and increased p16INK4A immunoreactivities correlate with higher grade of cervical intraepithelial neoplasia
D2-40 has been shown a selective marker for lymphatic endothelium, but also shown in the benign cervical basal cells. However, the application of D2-40 immunoreactivity in the cervical basal cells for identifying the grade of cervical intraepithelial neoplasia (CIN) has not been evaluated.